Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_assertion type Assertion NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_head.
- NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_assertion description "[The first human trial in cardiovascular disease started in 1994 treating peripheral vascular disease with vascular endothelial growth factor (VEGF) and since then, many different potent angiogenic growth factors have been tested in clinical trials for the treatment of peripheral arterial disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_provenance.
- NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_assertion evidence source_evidence_literature NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_provenance.
- NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_assertion SIO_000772 12499610 NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_provenance.
- NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_assertion wasDerivedFrom befree-20140225 NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_provenance.
- NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_assertion wasGeneratedBy ECO_0000203 NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_provenance.